Let-7 microRNA-binding-site polymorphism in the 3'UTR of KRAS and colorectal cancer outcome: A systematic review and meta-analysis

Cancer Medicine

Volumn 3, Issue 5, 2014, Pages 1385-1395

  Langevin, Scott M ^a   Christensen, Brock C ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Cetuximab; Lcs6; Prognosis; Progression; Rs61764370; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; LET 7 MICRORNA; MICRORNA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; KRAS PROTEIN, HUMAN; MIRNLET7 MICRORNA, HUMAN; ONCOPROTEIN; RAS PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER STAGING; CANCER SURVIVAL; COLORECTAL CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RNA BINDING; SYSTEMATIC REVIEW; WILD TYPE; CHEMISTRY; COLORECTAL TUMOR; GENETICS; MORTALITY; PROPORTIONAL HAZARDS MODEL;

3' UNTRANSLATED REGIONS; BINDING SITES; COLORECTAL NEOPLASMS; HUMANS; MICRORNAS; PATIENT OUTCOME ASSESSMENT; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84991434443     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.279     Document Type: Article

References (40)

1. Siegel, R., D. Naishadham, and A. Jemal. 2013. Cancer statistics, 2013. CA Cancer J. Clin. 63:11-30.
2. Van Cutsem, E., C. H. Kohne, E. Hitre, J. Zaluski, C. R. Chang Chien, A. Makhson, et al. 2009. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 360:1408-1417.
3. Cartwright, T. H. 2012. Treatment decisions after diagnosis of metastatic colorectal cancer. Clin. Colorectal Cancer 11:155-166.
4. Amado, R. G., M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, et al. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26:1626-1634.
5. Karapetis, C. S., S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, et al. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359:1757-1765.
6. Peeters, M., T. J. Price, A. Cervantes, A. F. Sobrero, M. Ducreux, Y. Hotko, et al. 2010. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28:4706-4713.
7. Van Cutsem, E., C. H. Kohne, I. Lang, G. Folprecht, M. P. Nowacki, S. Cascinu, et al. 2011. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol. 29:2011-2019.
8. Lin, A. Y., N. S. Buckley, A. T. Lu, N. B. Kouzminova, and S. R. Salpeter. 2011. Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth factor receptor monoclonal antibody therapy: a systematic review and meta-analysis. Clin. Colorectal Cancer 10:63-69.
9. Wilson, P. M., M. J. Labonte, and H. J. Lenz. 2010. Molecular markers in the treatment of metastatic colorectal cancer. Cancer J. 16:262-272.
10. Sharma, S. G., and M. L. Gulley. 2010. BRAF mutation testing in colorectal cancer. Arch. Pathol. Lab. Med. 134:1225-1228.
11. Eklof, V., M. L. Wikberg, S. Edin, A. M. Dahlin, B. A. Jonsson, Å. Öberg, et al. 2013. The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br. J. Cancer 108:2153-2163.
12. Johnson, S. M., H. Grosshans, J. Shingara, M. Byrom, R. Jarvis, A. Cheng, et al. 2005. RAS is regulated by the let-7 microRNA family. Cell 120:635-647.
13. Cerne, J. Z., V. Stegel, K. Gersak, and S. Novakovic. 2012. KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study. BMC Cancer 12:105.
14. Chin, L. J., E. Ratner, S. Leng, R. Zhai, S. Nallur, I. Babar, et al. 2008. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res. 68:8535-8540.
15. Hollestelle, A., C. Pelletier, M. Hooning, E. Crepin, M. Schutte, M. Look, et al. 2011. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res. Treat. 128:79-84.
16. Paranjape, T., H. Heneghan, R. Lindner, F. K. Keane, A. Hoffman, A. Hollestelle, et al. 2011. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol. 12:377-386.
17. Pilarski, R., D. A. Patel, J. Weitzel, T. McVeigh, J. J. Dorairaj, H. M. Heneghan, et al. 2012. The KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLoS ONE 7:e37891.
18. Ratner, E., L. Lu, M. Boeke, R. Barnett, S. Nallur, L. J. Chin, et al. 2010. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Res. 70:6509-6515.
19. Graziano, F., E. Canestrari, F. Loupakis, A. Ruzzo, N. Galluccio, D. Santini, et al. 2010. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. Pharmacogenomics J. 10:458-464.
20. Kjersem, J. B., T. Ikdahl, T. Guren, E. Skovlund, H. Sorbye, J. Hamfjord, et al. 2012. Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin ± cetuximab. BMC Cancer 12:534.
21. Ruzzo, A., F. Graziano, B. Vincenzi, E. Canestrari, G. Perrone, N. Galluccio, et al. 2012. High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. Oncologist 17:823-829.
22. Ryan, B. M., A. I. Robles, and C. C. Harris. 2012. KRAS-LCS6 genotype as a prognostic marker in early-stage CRC-letter. Clin. Cancer Res. 18:3487-3488. author reply 3489.
23. Sebio, A., L. Pare, D. Paez, J. Salazar, A. Gonzalez, N. Sala, et al. 2013. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenet. Genomics 23:142-147.
24. Smits, K. M., T. Paranjape, S. Nallur, K. A. Wouters, M. P. Weijenberg, L. J. Schouten, et al. 2011. A let-7 microRNA SNP in the KRAS 3'UTR is prognostic in early-stage colorectal cancer. Clin. Cancer Res. 17:7723-7731.
25. Zhang, W., M. J. Labonte, and H. J. Lenz. 2011. KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: does treatment combination partner matter? Ann. Oncol. 22:484-485.
26. Zhang, W., T. Winder, Y. Ning, A. Pohl, D. Yang, M. Kahn, et al. 2011. A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann. Oncol. 22:104-109.
27. Christensen, B. C., B. J. Moyer, M. Avissar, L. G. Ouellet, S. L. Plaza, M. D. McClean, et al. 2009. A let-7 microRNA-binding site polymorphism in the KRAS 3' UTR is associated with reduced survival in oral cancers. Carcinogenesis 30:1003-1007.
28. Ratner, E. S., F. K. Keane, R. Lindner, R. A. Tassi, T. Paranjape, M. Glasgow, et al. 2012. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 31:4559-4566.
29. Booth, A., M. Clarke, D. Ghersi, D. Moher, M. Petticrew and L. Stewart. 2011. An international registry of systematic-review protocols. Lancet 377:108-109.
30. Parmar, M. K., V. Torri, and L. Stewart. 1998. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17:2815-2834.
31. Michiels, S., P. Piedbois, S. Burdett, N. Syz, L. Stewart and J. P. Pignon. 2005. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int. J. Technol. Assess. Health Care 21:119-125.
32. Sterne, J. A. C., M. J. Bradburn, and M. Egger. 2001. Meta-analysis in Stata. Pp. 347-369 in M. Egger, G. Davey Smith, D. G. Altman, eds. Systematic reviews in health care: meta-analysis in context. 2nd ed. BMJ, London, U.K.
33. Higgins, J. P., and S. G. Thompson. 2002. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21:1539-1558.
34. Egger, M., G. Davey Smith, M. Schneider, and C. Minder. 1997. Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
35. Ruzzo, A., E. Canestrari, N. Galluccio, D. Santini, B. Vincenzi, G. Tonini, et al. 2011. Role of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patients. Ann. Oncol. 22:234-235.
36. Kundu, S. T., S. Nallur, T. Paranjape, M. Boeke, J. B. Weidhaas and F. J. Slack. 2012. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle 11:361-366.
37. Lettre, G., A. U. Jackson, C. Gieger, F. R. Schumacher, S. I. Berndt, S. Sanna, et al. 2008. Identification of ten loci associated with height highlights new biological pathways in human growth. Nat. Genet. 40:584-591.
38. Pan, X. M., R. F. Sun, Z. H. Li, X. M. Guo, Z. Zhang, H. J. Qin, et al. 2014. A let-7 KRAS rs712 polymorphism increases colorectal cancer risk. Tumour Biol. 35:831-835.
39. Heinemann, V., J. Y. Douillard, M. Ducreux, and M. Peeters. 2013. Targeted therapy in metastatic colorectal cancer-an example of personalised medicine in action. Cancer Treat. Rev. 39:592-601.
40. Moher, D., A. Liberati, J. Tetzlaff, and D. G. Altman. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535.